Abstract
The introduction of the Human papillomavirus (HPV) vaccination poses unique challenges due to its distinct characteristics. Unlike other vaccines, it is specifically designed to prevent cancer and is targeted towards adolescent females, making it difficult to implement within existing health intervention programs. Despite consistent clinical trial results confirming its effectiveness and safety, skepticism and concerns surrounding this vaccination are not uncommon, both among the general public and professionals. The HPV vaccination plays a crucial role in preventing cervical and other anogenital malignancies, even a single dose offering significant protection compared to not being vaccinated. This emphasizes the possibility of implementing a worldwide HPV vaccination program, as a solitary dose of the quadrivalent HPV vaccine exhibits immunogenicity and provides lasting protection against HPV 16 and 18 infections, comparable to the effectiveness of the two- and three-dose vaccine regimens.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
